Why T1D screening matters
T1D is a growing public health challenge. Without early detection, many individuals experience their first diagnosis during a life-threatening diabetic ketoacidosis (DKA) episode, a preventable emergency that can have lasting physical and psychological impacts, particularly in children.
Autoantibody screening offers a window of opportunity to identify at-risk individuals, such as children, before symptoms appear, when interventions can make the greatest difference.
| Stat1 | Context1 |
|---|---|
| 2.8M people with T1D in Europe | Rising 3.4% annually |
| 40-42% diagnosed via DKA | Preventable with early screening |
| 90% have no family history | Population-wide screening is essential |
Benefits of early detection
By identifying individuals at risk before the onset of symptoms, screening can have a profound impact on patient outcomes and quality of life.
Prevent emergencies
Access to new therapies
Informed care planning
Revvity's screening expertise
Revvity has been a trusted partner in newborn screening for decades, with our technology used in over 115 countries worldwide. We're now applying this same proven, scalable approach, including the convenience of dried blood spot (DBS) sample collection, to enable population-wide T1D autoantibody detection.
Key advantages:
- Scalable: enables large-scale screening programs, with flexible processing options for different laboratory volumes
- Reliable: built on proven newborn screening technology trusted in 115+ countries worldwide
- Efficient: DBS collection eliminates cold chain requirements, simplifying sample logistics for population screening initiatives
Screening options
Whether you're looking to bring T1D autoantibody screening into your laboratory or leverage our off-site laboratory testing services, Revvity has a solution to fit your needs.
| On-site laboratory testing | Off-site Revvity Omics lab services | |
|---|---|---|
| Best for | Labs with existing screening capabilities | Labs without in-house capacity |
| How it works | GSP T1D 3plex kit | Send DBS samples to Revvity Omics |
| Regulatory status | CE-IVD marked (Notified Body 0537) | Testing service (see disclaimer) |
| More information | Contact us | Learn more |
Screening landscape
T1D screening is rapidly evolving across Europe and beyond:
- Italy has introduced the first national T1D screening law
- Sweden, Germany, Denmark, Portugal, and the UK are conducting large-scale screening studies
- Revvity supports newborn screening programmes in over 115 countries, screening 33 million babies annually. As T1D screening programmes expand, Revvity is positioned to support laboratories and public health initiatives with proven, scalable technology.
- In partnership with European Diabetes Forum
- Uncover T1D is a screening program sponsored by Sanofi Canada, with testing services provided by Revvity Omics, learn more
Featured resources
References
- Ruiz-Grao, M. C., et al. (2024). Trends in the incidence of type 1 diabetes in European children and adolescents from 1994 to 2022: A systematic review and meta-analysis. PediatricDiabetes. https://doi.org/10.1155/2024/2338922
- Sims EK, et al. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes 2022;71:610–23.
- Simmons KM, Sims EK. Screening and prevention of type 1 diabetes: Where are we? J Clin Endocrinol Metab 2023;108:3067–79.
- Alonso GT, et al. Diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado children, 2010–2017. Diabetes Care 2020;43:117–21.
- T1D Exchange. (2023). FDA Approval of Teplizumab for Type 1 Diabetes. https://t1dexchange.org/articles/fda-approval-teplizumab-type-1-diabetes
GSP T1D 3plex kit is a CE marked in vitro diagnostic medical device, compliant with IVD Regulation (EU) 2017/746, certified by Notified Body number 0537.
Products may not be licensed in accordance with the laws in all countries, such as the United States. Please check with your local representative for availability.
Revvity Inc. does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.
Revvity Omics service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content of this presentation is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professional.
Interested in T1D screening? Talk to our experts.
Whether you are looking to bring T1D autoantibody screening into your laboratory or looking to leverage our Omics lab services, our team is here to help you get started.
